Development of a neurologic severity scale for Aicardi Goutières Syndrome

Laura Adang(Children's Hospital of Philadelphia), Adeline Vanderver(Children's Hospital of Philadelphia), Kimberly Kopin(Children's Hospital of Philadelphia), Jessica Galli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Kyle Peer(Children's Hospital of Philadelphia), Stacy V. Cusack(Children's Hospital of Philadelphia), Constance Besnier(Children's Hospital of Philadelphia), Francesco Gavazzi(Children's Hospital of Philadelphia), Elisa Fazzi(Centro Studi GISED), Valentina De Giorgis(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Micaela De Simone(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Justine Shults(Children's Hospital of Philadelphia), Abbas F. Jawad(Children's Hospital of Philadelphia), Simona Orcesi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino)
Molecular Genetics and Metabolism
April 2, 2020
10.1016/j.ymgme.2020.03.008
Cited by 49

Related Papers

Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
|The Lancet Neurology|2013|441
Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
|The Lancet Neurology|2020|326
Magnetic resonance imaging pattern recognition in hypomyelinating disorders
|Brain|2010|285
<i>GFAP</i> mutations, age at onset, and clinical subtypes in Alexander disease
|Neurology|2011|256
Janus Kinase Inhibition in the Aicardi–Goutières Syndrome
|New England Journal of Medicine|2020|201